INTRODUCTION
Gastric cancer (GC) is a very aggressive tumor and is currently the third leading cause of cancer-related deaths in both sexes at the world level (8.8% of the total) [1, 2] . At initial diagnosis, a significant proportion of Western GC patients (65%) are found to have unresec table disease or distant metastases. In Japan and South Korea, where nationwide governmentsponsored screening programs have been established, still up to 80% of patients who undergo a curative resection for GC develop locoregional or distant recurrence [2, 3] . The clinical management of patients with advanced GC remains one of the most challenging tasks in clinical oncology. Until recently, systemic chemotherapy alone has been the mainstay of treatment for these patients [4] . However, the disease often exhibits relative resistance to chemotherapeutic agents, and a satisfactory response is achieved only in a minority of the patients [5, 6] . In addition, although systemic chemotherapy can substantially increase symptom control and improve the patient's quality of life, its long-term results are still not satisfactory and unfortunately many patients die less than a year after starting therapy [5, 6] . Thus, there is undoubtedly a need to develop more effective treatment strategies for this formidable disease. As in other solid tumors, the uses of targeted agents that block vital inter and intracellular signaling path ways have recently emerged as a strategy for the treatment of advanced GC [7] [8] [9] [10] [11] [12] . Significant advances in our understanding of the underlying biologic processes of GC have recently expanded the number and range of potential therapeutic targets. Targeted agents may be used either alone or in combination with antineoplastic agents for patients with both chemotherapynaïve and chemotherapyrefractory disease. Some of these, such as trastuzumab and ramucirumab have been shown to have significant therapeutic activity and a good safety profile, have changed the treatment paradigm, and are therefore currently licensed in the United States and Europe as part of the management of patients with GC.
In this review, we will outline well-established targeted treatments for GC and discuss novel agents currently in development as well as some directions for future research.
Anti-epidermal growth factor receptor therapies
The epidermal growth factor receptor (EGFR) belongs to the ErbB family of receptor tyrosine kinases (RTK), which contains four closely related members: ErbB1 (HER1 or EGFR), ErbB2 (Her2/neu), ErbB3 and ErbB4 [13, 14] . EGFR activation by one of its ligands initiates diverse downstream signaling pathways including the RAS/RAF/ MAP kinase and PI3K/Akt/mTOR signaling networks. Both pathways play a vital role in several critical cellular processes including proliferation, growth, survival, motility, and tissue invasion [13, 14] . EGFR overexpression has been correlated with more aggressive tumor behavior and a worse clinical results in patients with GC, suggesting that EGFR is therapeutic target for this aggressive malignancy [13, 14] . The current therapeutic strategies targeting EGFR include neutralizing monoclonal antibodies (moAbs) directed against the extracellular receptor domain and small molecule tyrosine kinase inhibitors (TKIs) of the intracellular tyrosine kinase domain (Figure 1 ).
Cetuximab and panitumumab are engineered anti bodies that bind to EGFR with higher affinity compared to its natural ligands [15, 16] . Several phase II clinical trials have tested the feasibility of adding cetuximab to different chemotherapy regimens including 5FU/ folinic acid (LV)/irinotecan, 5FU/LV/oxaliplatin (FOLFOX), docetaxel/cisplatin, capecitabine/cisplatin, and capecitabine/oxaliplatin for chemotherapynaïve advanced GC patients [17] [18] [19] [20] . In these trials, overall response rates ranged from 41% to 69%, median progressionfree survival (PFS) varied from 5 to 8.5 mo, and median overall survival (OS) varied from 9 to 16.6 mo. A randomized phase II clinical study (CALGB 80403/ ECOG 1206) evaluated three different conventional chemotherapy regimens (Epirubicin, cisplatin and 5FU vs irinotecan and cisplatin vs FOLFOX) in combination with cetuximab. Response rates were 58%, 38%, and 51%, respectively, and median OS was 8.6 and 10 mo, respectively. Cetuximab combined with FOLFOX was found to be the least toxic of the three [21] . Unfortunately, these promising initial outcomes were not verified in the phase III EXPAND trial [22] . In this study, 904 previously untreated metastatic GC and gastroesophageal junction (GEJ) cancer patients were randomly allocated to receive chemotherapy (cisplatin and capecitabine) with or without cetuximab [22] . No differences in clinical outcome were found between treatment groups, and the primary and secondary efficacy endpoints were not met; the median PFS and OS were 4.4 mo (95%CI: 4.2 to 5.5 mo) and 9.4 mo (95%CI: 8.3 to 10.6 mo), respectively in the combined therapy group compared with 5.6 mo (95%CI: 5.1 to 5.7 mo) and 10.7 mo (95%CI: 9.4 to 11.3 mo), respectively in the chemotherapyalone group (P = 0.32 and P = 0.95 for PFS and OS, respectively). The addition of cetuximab also did not increase the overall response rate, which was 30% and 29% with or without cetuximab, respectively (Table 1) .
Similarly, the phase III REAL3 trial was performed to determine the effects of adding panitumumab to a combination chemotherapy regimen of epirubicin, oxaliplatin, and capecitabine (EOX) in patients with advanced esophagogastric adenocarcinoma [23] . In this trial, patients were randomly allocated to receive EOX or a modified EOX plus panitumumab. Disappointingly, adding panitumumab to EOX chemotherapy resulted in worsened OS [8.8 mo compared with 11.3 mo for the EOX regimen (HR = 1.37; P = 0.013)]. A trend toward a shorter PFS was also seen in patients receiving panitumumab (6.0 mo vs 7.4 mo, HR = 1.22; P = 0.068). The panitumumabcontaining arm was associated with an increased rate of grade 3-4 diarrhea (17% vs 11%), rash (11% vs 1%), mucositis (5% vs none), and hypomagnesaemia (5% vs none) but reduced rate of neutropenia (13% vs 28%).
Lastly, other novel humanized IgG1 antiEGFR moAbs including matuzumab and nimotuzumab have also been investigated as first-or second-line treatment for advanced GC, and have also failed to generate a strong efficacy signal [2426] . The small molecule EGFR TKIs have not been extensively studied in the treatment of advanced GC largely due to their limited activity in this setting [27, 28] . Why EGFRtargeting strategies have failed to be successful in this disease in spite of lack of activating KRAS mutations and in spite of good biologic rationale remains a mystery.
Anti-HER2 (ERBB2) therapy
As previously mentioned HER2 is another member of the ERB family of receptor tyrosine kinases [29] .
Overexpression and amplification of the HER2 is detected in 10%38% of GC patients [30] . Although the association between HER2 status and prognosis 
chemotherapy.
Lapatinib is an oral smallmolecule tyrosine kinase inhibitor of EGFR and HER2 that blocks their tyrosine kinase activities. Two phase III trials were performed to explore the effectiveness of lapatinib in first and second-line treatment of advanced GC. The LoGIC III trial investigated the efficacy of lapatinib when administered in combination with capecitabine plus oxaliplatin (CAPOX) as firstline therapy [34] . In total, 545 patients whose tumors overexpressed HER2 were assigned to receive CAPOX plus lapatinib or placebo. No significant difference in survival between the two treatment arms was detected. Median OS and PFS in the chemotherapy + lapatinib group were 12.2 and 6 mo, respectively, compared to 10.5 and 5.4 mo in the control group. Similarly, in the phase III TyTan trial conducted in Asia, 430 patients with advanced GC who had experienced failure of fluoropyrimidine and cisplatin based chemotherapy and exhibited FISHconfirmed HER2 amplification received lapatinib plus weekly paclitaxel or weekly paclitaxel alone [35] . Although, the addition of lapatinib to paclitaxel extended the primary endpoint of OS from a median of 8.9 mo to 11.0 mo, this improvement failed to reach statistical significance (P = 0.1044). The further subgroup analysis revealed a statistically significant benefit in both OS and PFS from the addition of lapatinib to chemotherapy in patients with HER2 IHC3+ tumors and in Chinese patients.
Targeting angiogenesis pathways
Angiogenesis is necessary for tumors to grow beyond a certain size, survive or spread. Vascular endothelial growth factor (VEGF) and its receptors (VEGFR1, VEGFR2 and VEGFR3) are important players in the development of this process. Binding of the ligand VEGFA to VEGFR2 triggers a signaling cascade leading to endothelial cell proliferation, migration, new vessel formation, and sustained angiogenesis [24] . Therefore, inhibition of the VEGF signaling has become a useful clinical maneuver in the treatment of several types of cancer.
Anti-VEGF moAb:
Bevacizumab is a fully human moAb targeting VEGFA [36] . The potential role of this drug in the management of patients with metastatic GC was evaluated in the phase III AVAGAST and AVATAR trials. The AVAGAST trial was global, randomized, placebo controlled trial conducted for evaluation of the benefits of bevacizumab when added to firstline capecitabine and cisplatin chemotherapy in 774 metastatic GC patients [37] . The trial did not show any significant improvement in OS in the bevacizumab cohort. Median OS was 12.1 mo with bevacizumab plus chemotherapy and 10.1 mo with placebo plus chemotherapy (HR = 0.87; 95%CI: 0.73 to 1.03; P = 0.1002). Despite this, both median PFS (6.7 mo vs 5.3 mo; HR = 0.80; 95%CI: 0.68 to 0.93; P = 0.0037) and overall response rate (46.0% vs 37.4%; P = 0.0315) were significantly increased by the addition of bevacizumab vs placebo. Preplanned subgroup analysis in GC still controversial, the results of some clinical studies have suggested that patients with HER2 negative disease have a more favorable prognosis than those with HER2 positive disease [29, 31] . Perhaps one of the most convincing data supporting the clinical benefits of targeted therapy in advanced GC come from the phase III ToGA study [32] . This landmark study investigated the addition of trastuzumab, a moAb that binds to the extracellular ligand binding domain of the HER2 receptor, to combination chemotherapy (cisplatin and either capecitabine or 5FU) in patients with previously untreated HER2 overexpressing [defined as HER2 fluorescence in situ hybridization (FISH) positive or immunohistochemistry (IHC) 3 positive], and advanced gastric or GEJ cancer. Over 3000 patients were screened for the study. Among the 594 enrolled patients, 296 received chemotherapy alone and 298 received chemotherapy plus trastuzumab. Patients receiving the combined therapy achieved improvement in all measures of efficacy including OS (13.8 mo vs 11.1 mo; HR = 0.74, P = 0.0046), PFS (6.7 mo vs 5.5 mo; HR = 0.71, P = 0.0002), and overall response rate (47% vs 35%, P = 0.0017). A post hoc subgroup analysis of the study demonstrated that the patients with strongly HER2 positive tumors (defined as IHC2+/ FISH+ or IHC3+) derived significant OS benefit from the addition of trastuzumab to chemotherapy (16 mo vs 11.8 mo, HR = 0.68). Moreover, the tolerability of the combination was good and there was no significant difference in the incidence of grade 3 or 4 side effects between the treatment groups. Based on these results, trastuzumab was approved in the Unites States and European Union for use in the firstline treatment of HER2overexpressing locally advanced or metastatic GC.
Pertuzumab is a new moAb that binds to the extracellular ligand binding domain of HER2 and blocks its dimerization with other HERfamily receptors [31] . When used together, the combination of pertuzumab plus trastuzumab provide a more comprehensive blockade of HER signalling than either agent alone. Therefore, the JACOB phase III study is currently recruiting participants to evaluate the effectiveness of pertuzumab in addition to trastuzumab plus chemotherapy (cisplatin plus capecitabine or 5FU) in chemonaïve patients with HER2overexpressing advanced gastric or GEJ cancer (NCT01774786).
Trastuzumab emtansine (TDM1) is a newly deve loped HER2targeted antibody-drug conjugate that links trastuzumab to a highly potent maytansine derived antimicrotubule drug (DM1) [33] . After binding the trastuzumab moiety to HER2 receptors on the tumor surface, TDM1 is internalized by endocytosis and degraded in lysosomes, resulting in release of DM1 containing cytotoxic catabolites [33] . A phase II-III trial (NCT01641939) is now investigating the effectiveness of TDM1 compared with taxanes (docetaxel or pacli taxel) in patients with metastatic HER2positive GC who develop progression of disease following firstline of the study also demonstrated geographical differences in the therapeutic effectiveness of bevacizumab treatment. A survival benefit for bevacizumab was demonstrated in patients recruited from North America and Latin America centers (median, 11.5 mo vs 6.8 mo for placebochemotherapy; HR = 0.63; 95%CI: 0.43 to 0.94), whereas patients recruited from Asia centers seemed to have no obvious benefit (HR = 0.97; 95%CI: 0.75 to 1.25). Subsequently, the study investigators identified plasma VEGFA levels and degree of tumor neuropilin1, a coreceptor for VEGFA, expression as potential predictive biomarkers of bevacizumab efficacy [38] . A negative OS correlation was found in patients with low expression of tumor neuropilin1 (HR = 0.75; 95%CI: 0.59 to 0.97) compared to those with high expression (HR = 1.07; 95%CI: 0.81 to 1.40; interaction P = 0.06). Of note, these findings were significant only in nonAsian patients.
AVATAR, a study similar in design to AVAGAST, was performed in Chinese patient population with advanced GC [39] . It was again demonstrated that the addition of bevacizumab to chemotherapy consisting capecitabine and cisplatin in this specific patient population did not improve OS (11.4 mo in the placebo arm vs 10.5 mo in the bevacizumab arm, HR = 1.11; P = 0.55).
Ramucirumab is a novel humanized IgG1 moAb that selectively binds to the extracellular ligand binding domain of VEGFR2 and blocks VEGFinduced angiogenic signaling [40] . In theory, this has the advantage of blocking signaling from VEGF isoforms other than VEGFA. Its efficacy and safety in advanced GC was evaluated in two international, phase III, randomized, doubleblinded and placebocontrolled studies. In the REGARD trial, a total 355 advanced gastric or GEJ cancer patients progressing after firstline platinum or fluoropyrimidinebased combination chemotherapy were randomized to receive best supportive care (BSC) plus either ramucirumab or placebo [41] . Ramucirumab was given intravenously every 2 wk at 8 mg/kg and the median treatment duration was 8 wk. Patients receiving ramucirumab had a significantly improved median OS (5.2 mo vs 3.8 mo; HR = 0.776; P = 0.0473) and PFS (2.1 mo vs 1.3 mo; HR = 0.483; P < 0.0001) than patients receiving placebo. The 12wk PFS rate was 40% for ramucirumab group and 16% for placebo group. Additionally, the overall response rate (3.4% vs 2.6%) and disease control rate (49% vs 23%) were also higher in the ramucirumab group compared to the placebo group (P < 0.0001). Ramucirumab had an acceptable toxicity profile. The most frequently recorded grade 3 or higher side effects in patients receiving ramucirumab were hypertension, anemia, abdominal pain, ascites, fatigue and hyponatremia. After presentation of these results, ramucirumab was approved for the secondline therapy advanced GC in the United States. Interestingly, these results are quite similar to those achieved with chemotherapy in the second-line setting [42] . The RAINBOW study tested ramucirumab in combi nation with paclitaxel in metastatic GEJ or gastric adenocarcinoma patients who experienced disease progression after firstline platinum and fluoropyri midinebased chemotherapy [43] . In this study, 665 patients were randomly assigned to receive ramuciru mab or placebo plus paclitaxel. OS was defined again primary endpoint for efficacy. Median OS for patients received ramucirumab plus paclitaxel was 9.6 mo, compared to 7.4 mo for those received paclitaxel alone (HR = 0.807; 95%CI: 0.6780.962; P = 0.0169). Median PFS was 4.4 mo and 2.9 mo, respectively (HR = 0.635; 95%CI: 0.5360.752; P < 0.0001). The objective response rate was higher in the combination arm compared to paclitaxel alone arm (28% vs 16%, P = 0.0001). Ramucirumab was relatively well tolerated. As expected, grade 3 or higher side effects were somewhat more frequent among patients receiving ramucirumab plus paclitaxel greater with combination treatment and included neutropenia, leukopenia, hypertension and fatigue. The RAINBOW study showed that an effective secondline treatment may improve the duration of survival in metastatic GC, and it is the only study to date to demonstrate a 2mo improvement in OS in this setting. Therefore, ramucirumab is the first antiangiogenic agent to demonstrate activity for advanced GC, and now approved both as monotherapy and in combination with paclitaxel for this malignancy.
Anti-VEGF TKI:
Apatinib is an orally administered TKI that selectively binds to VEGFR2 and inhibits VEGF induced endothelial cell proliferation and migration. As a result, it leads to a significant decrease in tumor microvessel density [44] . In a phase II trial conducted in China, apatinib was shown to increase PFS and OS in patients with metastatic GC progressing after 2 or more previous lines of chemotherapy [45] . Data from a phase III trial presented at the 2014 ASCO Annual Meeting confirmed the effectiveness of apatinib in this setting [46] . This trial included 273 patients with advanced GC who experienced disease progression after secondline treatment. Patients were randomly assigned to receive apatinib or placebo. The primary endpoint, median OS, was significantly longer in the apatinib group than in the placebo group (195 d vs 140 d; HR = 0.71; 95%CI: 0.540.94; P < 0.016). The apatinib group also had a better median PFS than the placebo group; 78 d vs 53 d, respectively (HR = 0.44; 95%CI: 0.330.61; P < 0.0001). Therefore, apatinib provides a new promising treatment option for advanced GC, although one which overlaps with ramucirumab in both degree of activity and mechanism.
Two multitargeted kinase inhibitors that share VEGF receptors as targets are sunitinib and sorafenib. Both of these agents have been tested in GC and have shown some signs of efficacy, but have not progressed to advanced trials [4749] . Given the modest activity and the toxicity profiles of these two agents, it is unlikely that they would supplant ramucirumab at this time and are no longer being studied in GC.
The mTOR pathway:
The mTOR (mammalian target of rapamycin) is an essential cellular signaling pathway that has a crucial role in the regulation of cell growth, survival, proliferation, metabolism, and angiogenesis [50] . Everolimus, an orally administered rapamycin analog, is the only mTOR inhibitor that has been evaluated in advanced GC [51] . Phase II trials documented that it can produce stabile disease in a significant portion of patients with chemorefractory advanced GC. Despite these promising data, in the phase III GRANITE1 trial, everolimus failed to demonstrate any significant improvement in OS compared to BSC alone [52] . In this study, advanced GC patients who had progressive disease after first-or second-line cytotoxic chemotherapy were randomized to receive everolimus treat ment (10 mg/d) or matching placebo in conjunction with BSC. Median OS was 5.4 mo for patients receiving everolimus and 4.3 mo for patients receiving placebo (HR = 0.90; 95%CI: 0.75 to 1.08; P = 0.124). Another phase III trial (AIOSTO0111) is now investigating the efficacy of everolimus when given in combination with paclitaxel in GC patients progressing following prior chemotherapy regimen.
Targeting the hepatocyte growth factor/c-MET signaling pathway
A transmembrane proteintyrosine kinase receptor cMET and its ligand, hepatocyte growth factor (HGF) control many vital cellular events such as cell proliferation, survival, motility, invasion and angiogenesis [53] . C-MET overexpression has been detected in 18%82% of GC patients, with genetic amplification of the CMET occurring in only 2%-3% of cases [54] . Patients with c-Met overexpressing tumors may have poorer survival, and the prognostic effect of overexpression seems to be independent of disease stage [53] . Therefore, c-MET has been recognized as potentially significant therapeutic target in GC.
Rilotumumab is a fully humanized IgG2 moAb that selectively binds HGF and prevents its binding to the MET receptor [53] . The results of a phase Ib/II study of rilotumumab in combination with platinumbased chemotherapy in patients with locally advanced or metastatic GC have demonstrated the potential thera peutic value of drugs that target the cMET pathway in this disease [55] . In the phase II part of this study, 121 patients were randomized to ECX regimen plus placebo (n = 39) or ECX plus either 7.5 mg/kg (n = 42) or 15 mg/kg (n = 40) rilotumumab. Median PFS was 5.1 mo (2.97.0) in the rilotumumab 15 mg/kg group, 6.8 mo (4.57.5) in the rilotumumab 7.5 mg/kg group, 5.7 mo (4.57.0) in both rilotumumab groups combined, and 4.2 mo (2.94.9) in the placebo group. The HR for PFS compared with placebo was 0.69 (80%CI: 0.490.97; P = 0.164) for rilotumumab 15 mg/kg, 0.53 (80%CI: 0.380.73; P = 0.009) for rilotumumab 7.5 mg/kg, and 0.60 (80%CI: 0.450.79; P = 0.016) for combined rilotumumab. Rilotumumab was generally well tolerated by patients, with common side effects including neutro penia, anemia, thrombocytopenia, peripheral edema, and deep vein thrombosis. The association between MET expression and clinical outcomes was also evaluated in this trial. MET expression was found to be prognostic for shortened OS in the placebo group (5.7 mo vs 11.5 mo). In the subgroup of patients with increased MET expression, median OS was longer in patients receiving rilotumumab than in those receiving placebo (10.6 mo vs 5.7 mo). However, no survival benefit was seen with the addition of rilotumumab to chemotherapy among METnegative patients.
Based on these data, the RILOMET1 [a multicenter, randomized, doubleblind, placebocontrolled phase III study of rilotumumab (15 mg/kg) plus ECX regimen as firstline therapy for metastatic METpositive gastric or GEJ adenocarcinoma] and the RILOMET2 trial (a multicenter, randomized, doubleblind, placebo controlled phase III study of rilotumumab plus cisplatin and capecitabine regimen as firstline therapy for Asian patients with metastatic METpositive gastric or GEJ cancer) have been conducted. Unfortunately, the RILOMET1 study has been reported as negative via press release (AMGEN press release), with final presentation of data pending at an upcoming meeting.
Onartuzumab is an Escherichia coliderived humanized monovalent moAb against MET that specifically binds to the MET receptor and blocks HGFMET binding [56] . Shah et al [57] have presented the results of a phase II trial that compared FOLFOX plus onartuzumab vs FOLFOX plus placebo in patients with metastatic gastroesophageal adenocarcinoma. The primary endpoint of the trial was not met (6.77 mo in onartuzumab arm vs 6.97 mo in the placebo arm, HR = 1.08; 95%CI: 0.711.63). In MET positive patients, PFS was 5.95 mo for patients receiving onartuzumab vs 6.8 mo for those in the placebo arm (HR = 1.38; 95%CI: 0.603.20). Serious adverse events, including neutropenia, thrombocytopenia, peripheral edema, and pulmonary embolism also occurred more frequently in patients on onartuzumab (55% vs 40%).
The phase III MetGastric trial will assess the effectiveness and toxicity of onartuzumab in combination with modifiedFOLFOX6 chemotherapy in patients with metastatic HER2negative and METpositive gastric or GEJ adenocarcinoma [58] . In this study, enrolled patients will receive the chemotherapy with either onartuzumab or placebo, and patients who have not progressed after 12 cycles of treatment will continue with either onartuzumab or placebo until evidence of disease progression or intolerable toxicity.
Targeting programmed cell death-1 receptor and its ligand Programmed cell death-1 (PD1) is a cell surface and immune inhibitory receptor expressed on a variety of immune cells, especially cytotoxic T cells. Two distinct ligands for PD1 were identified: Programmed death ligand 1 (PDL1) and PDL2 [59] . While PDL2 is expressed mainly on macrophages and dendritic cells, PDL1 is expressed exclusively by tumor cells and their microenvironment [60] . Tumors that express PDL1 often tend to be aggressive and carry a poor prognosis [61] . Tumor cells utilize the PD1/PDL1 pathway to evade immunecell attack. Activation of this pathway in tumor cells blocks T-cell-mediated cytotoxicity and allows tumor cells to continue to proliferate [5961] . Drugs targeting PDL1 pathway may stimulate antitumor immunity, especially (although not exclusively) in PDL1 positive tumors.
At the 2014 European Society for Medical Oncology meeting, data on safety and tolerability, and preliminary antitumor efficacy of pembrolizumab in advanced GC patients were presented by Muro et al [62] (KEYNOTE012 study). This drug is a selective and humanized moAb that blocks interaction between PD1 and its ligands PDL1 and PDL2. Muro et al [62] enrolled 39 patients with PDL1 positive advanced GC: 19 from AsiaPacific, 20 from rest of world. Sixtyseven percent of these patients had received more than 2 chemotherapy lines. Pembrolizumab was administered 10 mg/kg once every 2 wk for up to 24 mo in the absence of intolerable toxicity or disease progression. The overall response rate was 31.6% in patients in the AsiaPacific region and 30% in patients from rest the world. Median duration of response has not yet been reached at the time of initial presentation, but ranged from 8+ to 20+ wk. Four patients developed grade 35 drugrelated adverse events including peripheral sensory neuropathy, fatigue, decreased appetite, hypoxia, and pneumonitis (n = 1 each). One treatmentrelated death was recorded due to hypoxia. The authors of the study have concluded that pembrolizumab treatment seems to have and acceptable safety and tolerability profile and it provides encouraging clinical antitumor activity in chemo-refractory disease.
On the basis of these promising preliminary data, phase II KEYNOTE059 study will be initiated to evaluate pembrolizumab as single agent or in combination with cisplatin and 5FU in patients with metastatic PDL1 positive gastric or GEJ adenocarcinoma. [63] . Additionally, EBVpositive gastric cancers preferentially overexpress CD274 and PDCD1LG2 (PDL1 and PDL2) that were discussed above [64] . These are currently being evaluated as predictive biomarkers for immune checkpoint inhibitor activity [65, 66] . In addition, this subgroup has significant promoter hypermethylation, such that evaluating hypomethylating agents such as azacitidine, decitabine and others in clinical development might represent a promising strategy.
Recent analysis from the Gastric Cancer Genome
The MSIhigh genotype is associated with high mutational rate, representing a wealth of antigens that could be recognized by the immune system [67, 68] . This genotype has been proposed to be responsive to checkpoint inhibitors, and clinical trials are ongoing (NCT01876511, NCT02060188) addressing response to checkpoint inhibitors in MSI high gastrointestinal cancers.
Other mutations that have been reported (KRAS, P53, APC, and CTNNB1) are still challenging to target and are the subject of numerous reviews. Knowledge of frequency of mutation of these genes, however, provides impetus for further basic research. For example, cell cycle regulators could have better chance of activity in P53 mutant tumors [69, 70] . Lastly, the WNT/beta catenin pathway is currently a focus of much preclinical and clinical research [71] .
CONCLUSION
Gastric cancer has long represented one of the most difficult gastrointestinal malignancies to treat. Encour agingly, recent progress with targeted therapies offers hope for patients with advanced GC, and expands the therapeutic armamentarium considerably against this formidable disease. As these therapies continue to be developed, we must focus on determination of predictive markers, and preferably codevelop drugs with these markers. The mechanisms underlying primary or acquired resistance to targeted agents also should be clarified in order to help further drug development. We propose a treatment algorithm that is consistent with current National Cancer Center Network guidelines (version 3, 2015) and that integrates targeted therapies into the management of advanced GC (Figure 2 ). The addition of trastuzumab to a firstline chemotherapy doublet (cisplatin and capecitabine or 5FU) is now considered standard of care for patients with HER2 positive advanced GC. The results of the phase III JACOB trial are awaited with great interest to see if the combined use of trastuzumab and pertuzumab can improve clinical outcome. Antiangiogenic therapy has failed to meet the expectations as firstline treatment. But secondline treatment with ramucirumab or apa tinib now represents a good alternative for chemo refractory GC patients for whom the options are still are quite limited. Other targeted agents currently under evaluation in clinical trials including inhibitors of mTOR, cMET, IGFR, and FGFR pathways can help expand our treatment repertoire in the future against advanced GC. Lastly, knowledge gained from detailed molecular profiling of gastric cancers gives us a roadmap for future basic and clinical research.
